Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$2.09 USD
-0.07 (-3.24%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $2.10 +0.01 (0.48%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Amylyx Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 381 | 22 | 0 | 1 | NA |
Cost Of Goods | 25 | 3 | 0 | 0 | NA |
Gross Profit | 355 | 19 | 0 | 1 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 317 | 221 | 83 | 40 | 0 |
Income After Depreciation & Amortization | 39 | -201 | -83 | -39 | 0 |
Non-Operating Income | 16 | 4 | -5 | -1 | NA |
Interest Expense | 0 | 0 | 0 | 2 | NA |
Pretax Income | 54 | -198 | -88 | -42 | NA |
Income Taxes | 5 | 1 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | 49 | -198 | -88 | -42 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | 49 | -198 | -88 | -42 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 30 | -203 | -83 | -39 | 0 |
Depreciation & Amortization (Cash Flow) | -9 | -2 | 0 | 0 | NA |
Income After Depreciation & Amortization | 39 | -201 | -83 | -39 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 69.99 | 58.50 | 6.59 | NA | NA |
Diluted EPS Before Non-Recurring Items | 0.70 | -3.39 | -13.35 | NA | NA |
Diluted Net EPS (GAAP) | 0.70 | -3.39 | -13.35 | NA | NA |
Fiscal Year end for Amylyx Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | -1.02 | 88.64 | 108.45 | 102.69 | 98.22 |
Cost Of Goods | 7.42 | 116.41 | 9.36 | 5.22 | 5.58 |
Gross Profit | -8.44 | -27.76 | 99.09 | 97.48 | 92.64 |
SG&A, R&D, and Dept/Amort Expenses | 67.85 | 94.37 | 97.15 | 78.76 | 72.43 |
Income After SG&A, R&D, and Dept/Amort Expenses | -76.29 | -122.13 | 1.94 | 18.72 | 20.21 |
Non-Operating Income | 3.59 | 3.58 | 4.54 | 3.69 | 3.81 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -72.70 | -118.55 | 6.48 | 22.41 | 24.01 |
Income Taxes | 0.00 | 0.24 | 1.75 | 1.52 | 1.93 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -72.70 | -118.79 | 4.73 | 20.89 | 22.07 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -72.70 | -118.79 | 4.73 | 20.89 | 22.07 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 68.03 | 67.85 | 69.20 | 69.75 | 70.13 |
Diluted EPS Before Non-Recurring Items | -0.73 | -0.46 | 0.07 | 0.30 | 0.31 |
Diluted Net EPS (GAAP) | -1.07 | -1.75 | 0.07 | 0.30 | 0.31 |